A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs TK 216 (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions; First in man
- Sponsors Oncternal Therapeutics, Inc.; Tokalas, Inc.
- 02 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, nine patients have been enrolled till date.
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 30 Aug 2016 According to Oncternal Therapeutics media release, company announced that first patient has been dosed in this study.